EOLS

Vorhandelsmarkt: 12.04 -0.18 -1.47%

Evolus Inc (EOLS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Evolus Inc Stock (EOLS) Company Profile

Healthcare (1161)

(949) 284-4555

520 NEWPORT CENTER DRIVE, NEWPORT BEACH

@evolusaesthetic

Nächster Verdiensttermin

Neueste SEC-Einreichungen

EOLS's Discussions on Twitter

Vergleichen Sie EOLS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EOLS Evolus Inc	12.22	762.41M	202.09M	-61.69M	-35.64M	-1.08
ZTS Zoetis Inc	163.50	72.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	14.98	47.08B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.16	45.99B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.29	17.52B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	312.26	13.78B	2.76B	1.11B	898.10M	22.77

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-29	Hochstufung	Barclays	Equal Weight → Overweight
2022-06-23	Eingeleitet	Needham	Buy
2022-05-12	Hochstufung	Barclays	Underweight → Equal Weight
2022-01-20	Hochstufung	Truist	Hold → Buy
2021-05-06	Hochstufung	Mizuho	Neutral → Buy
2021-04-08	Bestätigt	H.C. Wainwright	Buy
2021-02-24	Herabstufung	Truist	Buy → Hold
2020-07-07	Herabstufung	Mizuho	Buy → Neutral
2020-02-06	Fortgesetzt	Mizuho	Buy
2019-11-26	Eingeleitet	SVB Leerink	Outperform
2019-09-05	Fortgesetzt	Mizuho	Buy
2019-06-28	Eingeleitet	Wells Fargo	Market Perform
2019-06-11	Eingeleitet	Barclays	Underweight
2019-03-20	Eingeleitet	SunTrust	Buy
2019-02-14	Eingeleitet	H.C. Wainwright	Buy
2019-01-29	Eingeleitet	Stifel	Buy

Alle ansehen

Evolus Inc Aktie (EOLS) Neueste Nachrichten

Finanzdaten der Evolus Inc-Aktie (EOLS)

Evolus Inc (EOLS)

Evolus Inc Stock (EOLS) Company Profile

Vergleichen Sie EOLS mit anderen Aktien

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Evolus Inc Aktie (EOLS) Neueste Nachrichten

Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty - MSN

Evolus CEO David Moatazedi sells $77,512 in stock By Investing.com - Investing.com Australia

Evolus CEO David Moatazedi sells $77,512 in stock - Investing.com India

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference - BioSpace

Evolus Inc (EOLS) Shares Down 4.54% on Mar 25 - GuruFocus

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 - BioSpace

Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain - Yahoo

Evolus reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:17 pm EDT - MarketScreener

Evolus director David Moatazedi sells $1.37 million in stock By Investing.com - Investing.com Australia

Evolus Growth Continues: 14 New Employees Join as Company Strengthens Talent Pool - Stock Titan

Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference - Business Wire

Evolus executive Avelar Rui sells $369,867 in stock By Investing.com - Investing.com South Africa

Evolus CFO Sandra Beaver sells $119,242 in company stock By Investing.com - Investing.com South Africa

Evolus chief marketing officer sells $60,124 in common stock By Investing.com - Investing.com South Africa

Evolus CFO Sandra Beaver sells $119,242 in company stock - Investing.com

Evolus executive Avelar Rui sells $369,867 in stock - Investing.com India

Evolus director David Moatazedi sells $1.37 million in stock - Investing.com India

Evolus chief marketing officer sells $60,124 in common stock - Investing.com

When the Price of (EOLS) Talks, People Listen - news.stocktradersdaily.com

Evolus Executives Sell Shares to Cover Tax Obligations - TradingView

Trade Alert: Independent Director Of Evolus Karah Parschauer Has Sold Stock - Simply Wall St

Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting - Business Wire

Evolus director Parschauer sells $167,465 in common stock - Investing.com India

Evolus director Parschauer sells $167,465 in common stock By Investing.com - Investing.com South Africa

Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands - Investing.com India

Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands By Investing.com - Investing.com South Africa

Evolus at Barclays Conference: Strategic Growth and New Launch - Investing.com

Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights - Investing.com India

Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas - The Motley Fool

What is HC Wainwright’s Estimate for Evolus FY2025 Earnings? - Defense World

(EOLS) Investment Analysis - Stock Traders Daily

Global Jeuveau Market Outlook 2025-2034: Growth Drivers, Share, And Trends - EIN News

Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Principal Financial Group Inc. - Defense World

Evolus, Inc. to Host Earnings Call - ACCESS Newswire

Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Rhumbline Advisers - Defense World

IFP Advisors Inc Has $52,000 Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World

Evolus’s Strong Market Position and Growth Potential Highlighted by Robust Revenues and Strategic Expansions - TipRanks

HC Wainwright Reaffirms “Buy” Rating for Evolus (NASDAQ:EOLS) - Defense World

Evolus’s Promising Growth and Strategic Positioning Earns a ‘Buy’ Rating from Analyst Douglas Tsao - TipRanks

Evolus, Inc. Earnings Call Highlights Robust Growth and Profitability - TipRanks

Evolus Inc Reports Q4 2024 Revenue of $79 Million, Surpassing Es - GuruFocus.com

Stifel maintains Buy on Evolus stock, sets $25 target By Investing.com - Investing.com UK

H.C. Wainwright maintains Buy rating on Evolus stock at $27 target By Investing.com - Investing.com South Africa

H.C. Wainwright maintains Buy rating on Evolus stock at $27 target - Investing.com

Evolus Celebrates Strong Demand For Jeuveau Wrinkle Treatment - Finimize

Assessing Evolus: Insights From 6 Financial Analysts - Benzinga

Evolus price target raised to $25 from $22 at Barclays - TipRanks

Finanzdaten der Evolus Inc-Aktie (EOLS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie EOLS